53P ‘HER2-LOW’ breast cancer brain metastases: An opportunity for targeted systemic therapies in a high-need patient population

Abstract

The landscape of systemic therapies available for treating BrM has recently expanded to include new HER2-targeted tyrosine kinase inhibitors and antibody-drug conjugates for patients with HER2-positive metastatic breast cancer (MBC). Given that HER2-targeted therapies are now being investigated among patients whose disease does not meet established cut points for HER2 expression, we examined the proportion of patients with “HER2-low” in breast cancer brain metastases BrM.